Biosimilars Objectives:

· Define biosimilars, extrapolation of indications, and interchangeability on the basis of FDA definitions and guidance

· Explain the similarities/differences between biosimilars and originator (reference) biologics, as well as the difference between the terms biosimilar and generic

· Evaluate key aspects of current FDA guidance that inform the health care provider’s knowledge of the biosimilar approval process, manufacturing, and naming, as well as state regulations surrounding substitution practices

· Apply foundational knowledge on biosimilars to clinical situations relevant to hematology/oncology practice